Elizaveta M. Pnachina

Elizaveta M. Pnachina

Auto-generated profile, based on publicly available information

Elizaveta M. Pnachina

N. I. Lobachevsky State University of Nizhny Novgorod

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
NKNatalia Kuzmina
Natalia Kuzmina
GGGalina P. Gribova
Galina P. Gribova
EPElizaveta M. Pnachina
Elizaveta M. Pnachina
LKLiubov Krylova
Liubov Krylova
EFEkaterina A. Fedotova
Ekaterina A. Fedotova
Vasilii OtvaginVasilii Otvagin
Vasilii Otvagin
Latest studies highlight boron-dipyrromethene (BODIPY) with meso-methyl moiety as a promising photoremovable protecting group due to its activation within the phototherapeutic window. While BODIPYs inherently generate ROS and act as photosensitizers, few studies have explored combining their photouncaging capability with photodynamic therapy (PDT). Herein, we developed novel meso-methyl-BODIPY conjugates of the DNA alkylator Boc-seco-CBI and the multikinase inhibitor cabozantinib derivative, activated by green or red light. To enhance photodecaging efficiency of conjugates, heavy atoms (Br, I) were introduced, and the boron atom was alkylated. The synthesized compounds were characterized for key photophysical and photochemical properties, including quantum yields of singlet oxygen generation, fluorescence, photolysis and cytostatic release. It was shown, that green-light irradiation of halogenated Boc-seco-CBI conjugates enabled rapid cytostatic release (<1 min), though with modest drug yields due to competing photodegradation. However, efficient uncaging of the cytostatic from the BODIPY-cabozantinib conjugate was achieved only after extended photoirradiation (~80 min) with red light. In vitro evaluation using tumor (MDA-MB-231, A431) and normal (HEK293) cell lines with various EGFR/c-Met expression demonstrated that the BODIPY-cabozantinib conjugate exhibited predominant photosensitizing effects, with minimal cytostatic contribution. During this study, we encountered significant synthetic challenges in developing red-light-absorbing conjugates, coupled with their photodegradation under prolonged irradiation. Our observations reveal key considerations for developing conjugates based on meso-methyl-BODIPY that combine PDT with light-controlled drug release toward antitumor therapy.

30 June 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
EKEkaterina Kudriashova
Ekaterina Kudriashova
MYMargarita A. Yarushina
Margarita A. Yarushina
IVIlya I. Vorobyov
Ilya I. Vorobyov
EFEkaterina A. Fedotova
Ekaterina A. Fedotova
EPElizaveta M. Pnachina
Elizaveta M. Pnachina
Vasilii OtvaginVasilii Otvagin
Vasilii Otvagin
Acetophenone-derived bis-Mannich bases, known for their bioactivity and potential to act as Michael acceptors via deamination and acrolein-type release, have historically suffered from low-yielding syntheses due to their instability. We report a simple, high-yielding (80–90% in most cases), scalable method using TMMDA and ZnCl₂ that eliminates the need for chromatographic purification. Mechanistic and DFT studies revealed that TMMDA functions as both a base and iminium precursor, while ZnCl₂ promotes acetophenone enolization and stabilizes the products. Notably, these bis-Mannich bases exhibit unprecedented reactivity with N-nucleophiles in aqueous media, forming hexahydro-pyrimidine and diazabicyclo[3.2.1]octane scaffolds. This transformation was successfully applied in the late-stage func-tionalization of erlotinib, including conjugation with the αvβ3-targeting cyclo(RGDfK) peptide. In vitro studies revealed enhanced nonspecific antiproliferative activity for erlotinib derivatives, likely driven by deamination and subsequent Michael addition to abundant nucleophiles in biomolecules. Overall, this work reestablishes bis-Mannich bases as versatile intermediates for heterocycle synthesis and drug modification.